XGN

EXAGEN INC

Healthcare | Micro Cap

-$0.17

EPS Forecast

$19.1

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Exagen Inc. Q3 2026: Revenue Rises, Loss Narrows as Precision Medicine Firm Bends Toward Profitability

Ticker: Nasdaq:XGN. In this early look at Exagen’s results, EPS figures aren’t detailed in the excerpt, but investors will be watching for EPS consensus and any potential earnings surprise against the revenue forecast as the company reports its third quarter 2026 numbers.

Overview

Exagen Inc., a Carlsbad, Calif.-based precision medicine company focused on autoimmune disease, released its third-quarter 2026 results on November 10, 2026. The press materials emphasize topline progress and margin discipline as the company continues its path toward sustainable profitability in a sector known for clinical complexity and payer negotiations.

Key Financials

Revenue for the quarter ended September 30, 2026: $18.417 million (reported in thousands, as shown in the filing). On a year‑to‑date basis, revenue for the nine months ended September 30, 2026 totaled about $55.664 million.

The company framed the quarter as a continuation of growth, noting that Third Quarter Revenue grew 7% year over year. Year-to-date revenue grew 11% versus the prior year period.

Gross margin stood at 58.8% for the quarter and roughly 58.4% for the nine months ended September 30, indicating a steadying mix and pricing dynamics despite ongoing expenses.

On the profitability line, the report highlights a net loss reduced by 12% and an Adjusted EBITDA loss improved by over 30%, underscoring cost discipline and operating leverage efforts even as the company remains in a loss-making phase.

The filing notes the metrics are unaudited and presented in thousands, with ASP data also referenced in the table. Exagen’s disclosure emphasizes revenue growth and margin stability as hallmarks of its current trajectory.

What It Signals for Exagen and the Sector

In a market for autoimmune diagnostics where the moat often comes from test accuracy, payer willingness to reimburse, and the cost of clinical development, Exagen’s quarter shows the kind of progress that keeps investors interested without promising immediate profitability. A 7% quarterly uptick in revenue, paired with a double‑digit year‑to‑date gain, suggests demand strength or at least resilience in the company’s assay portfolio.

The margin data, hovering near the high‑50s for gross margin, imply that the product mix and pricing discipline remain favorable, even as the company manages operating expenses. The notable improvement in Adjusted EBITDA loss—more than 30%—is an encouraging signal that the company is squeezing operating leverage, though it’s important to recognize that this is still a loss on an absolute basis.

In the near term, investors will be evaluating how Exagen translates these top- and bottom-line indicators into a clearer EPS trajectory. The absence of an explicit EPS figure in this excerpt means market participants will vigilantly compare reported earnings per share against the EPS consensus in forthcoming releases. Any potential earnings surprise—positive or negative—will hinge on how well the company can convert revenue momentum and margin stability into sustained profitability.

For sector peers, Exagen’s path underscores a familiar narrative: growth in specialized diagnostics often accompanies a period of investment in scale and payer negotiations. The degree to which Exagen can translate improving gross margins and reduced losses into a durable earnings profile could influence how investors price other precision medicine and autoimmune-disease players, particularly those with similar cost structures or test‑volume dynamics.

Outlook and Investor Takeaways

The press release focuses on quarterly and year-to-date performance, but the absence of forward-looking guidance in this excerpt means the market will be waiting for additional color on expectations for the remainder of 2026 and beyond. Key questions include: Will Exagen provide a clear revenue forecast for the upcoming quarters or year, and where does EPS consensus sit in relation to current burn rates and capex plans?

If the company can sustain revenue growth while continuing to improve adjusted profitability, the stock could begin to price in a longer runway to earnings, narrowing the gap between net loss and cash generation. Until then, the narrative remains a delicate balance between early-stage profitability signals and the realities of a high‑margin, high‑cost diagnostic business.

Implications for Peers in the Autoimmune Diagnostics Space

Exagen’s quarterly rhythm—modest revenue expansion, steady gross margins, and meaningful improvements in non-GAAP profitability metrics—creates a useful benchmark for peers navigating payer coverage, test adoption, and the economics of clinical labs. For sector peers, the message is clear: margin discipline and a credible path to EBITDA profitability remain critical levers as investors scrutinize earnings quality alongside top-line growth.

Source: Exagen Inc. press release (Third Quarter 2026 results). All figures in thousands unless noted otherwise; percentages reflect the reported periods.